Computational reactive–diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Giuseppina Barbieri(Istituti Ospitalieri di Cremona), Giovanni Scambia(Agostino Gemelli University Polyclinic), Carlo Azzini(Istituti Ospitalieri di Cremona), Ida Paris(Agostino Gemelli University Polyclinic), Giuseppina Ferrero(Istituti Ospitalieri di Cremona), Gianpaolo Ruocco(University of Basilicata), Marco Ungari(Istituti Ospitalieri di Cremona), Maria Rosa Cappelletti(University of Trieste), Valeria Cervoni(University of Trieste), Sergio Aguggini(Istituti Ospitalieri di Cremona), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Ignazio Ciliberto(University of Trieste), Maria Valeria De Bonis(University of Basilicata), Manuela Milani(Humanitas University), Mariavittoria Locci
Cited by 6
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Outcome of Cesarean scar pregnancy managed expectantly: systematic review and meta‐analysis
|Ultrasound in Obstetrics and Gynecology|2017|299